Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock

About Swedish Orphan Biovitrum AB (publ)

Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Its primary therapeutic focus areas encompass hematology, immunology, and a range of genetic and metabolic disorders, with a commercial presence across Europe, North America, and other international markets. The company's diverse portfolio includes medications addressing critical conditions such as hemophilia B (Alprolix) and hemophilia A (Elocta), thrombocytopenia (Doptelet), hemophagocytic lymphohistiocytosis (Gamifant), and hereditary tyrosinemia type-1 (Orfadin). Additionally, it provides Kineret for multiple inflammatory diseases, including cryopyrin-associated periodic syndrome, rheumatoid arthritis, and Still's disease, alongside Synagis for severe lower respiratory tract infections. Sobi's broader product range further comprises various other therapeutics like Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. Beyond its proprietary offerings, Sobi is involved in the development of drug substances for external partners, notably ReFacto AF/Xyntha for Pfizer, as well as advancing BIVV001 for hemophilia A and Nirsevimab, which targets respiratory syncytial virus. A key strategic collaboration exists with Apellis Pharmaceuticals Inc. for the co-development of pegcetacoplan, aimed at treating a spectrum of rare diseases, such as paroxysmal nocturnal hemoglobinuria. The company maintains its headquarters in Solna, Sweden.

Swedish Orphan Biovitrum AB (publ) is headquartered in SE.

Swedish Orphan Biovitrum AB (publ) (BIOVF) stock trades at $49.03 with a market capitalization of $16.96B. The stock is valued at a price-to-earnings (P/E) ratio of 173.58, price-to-book of 3.94, price-to-sales of 5.49. Over the past 52 weeks the stock has ranged between $28.94 and $49.03, and currently trades at its 52-week high.

On profitability, Swedish Orphan Biovitrum AB (publ) generates a return on equity (ROE) of 2.41%, return on capital employed of 14.37%, an operating margin of 29.56%, a net profit margin of 3.18%.

In its most recent fiscal year, Swedish Orphan Biovitrum AB (publ) reported annual revenue of $28.2B, net profit of $477.0M, revenue has compounded at 13.0% a year over the last five years, profit at -31.9% a year.

The balance sheet shows a debt-to-equity ratio of 0.47 — a conservative balance sheet with little leverage risk, a current ratio of 0.70, total assets of $67.3B, $1.0B in cash and equivalents.

BIOVF has an average daily trading volume of 13 shares, a beta of 0.29 (less volatile than the overall market).

Official website: www.sobi.com